Cite
Organometallic ruthenium anticancer complexes inhibit human peroxiredoxin I activity by binding to and inducing oxidation of its catalytic cysteine residue.
MLA
Lin, Yu, et al. “Organometallic Ruthenium Anticancer Complexes Inhibit Human Peroxiredoxin I Activity by Binding to and Inducing Oxidation of Its Catalytic Cysteine Residue.” Metallomics : Integrated Biometal Science, vol. 11, no. 3, Mar. 2019, pp. 546–55. EBSCOhost, https://doi.org/10.1039/c8mt00352a.
APA
Lin, Y., Wang, J., Zheng, W., Luo, Q., Wu, K., Du, J., Zhao, Y., & Wang, F. (2019). Organometallic ruthenium anticancer complexes inhibit human peroxiredoxin I activity by binding to and inducing oxidation of its catalytic cysteine residue. Metallomics : Integrated Biometal Science, 11(3), 546–555. https://doi.org/10.1039/c8mt00352a
Chicago
Lin, Yu, Jie Wang, Wei Zheng, Qun Luo, Kui Wu, Jun Du, Yao Zhao, and Fuyi Wang. 2019. “Organometallic Ruthenium Anticancer Complexes Inhibit Human Peroxiredoxin I Activity by Binding to and Inducing Oxidation of Its Catalytic Cysteine Residue.” Metallomics : Integrated Biometal Science 11 (3): 546–55. doi:10.1039/c8mt00352a.